ZyVersa Therapeutics Highlights Data from Review Article Published in Nature Reinforcing IC 100’s Rationale for Inhibiting ASC and ASC Specks to Attenuate Damaging Inflammation Associated with Various Conditions, Including Obesity and Its Complications
February 28, 2024 07:57 ET
|
ZyVersa Therapeutics
In obesity, inflammasome activation in fat tissue triggers cell death and release of inflammatory cytokines & ASC Specks, spreading damaging inflammation.
ZyVersa Therapeutics Publishes New White Paper Detailing the Role of Inflammasomes and ASC Specks in Neurological Diseases, and Data Supporting Inflammasome ASC Inhibitor IC 100 as a Potential Therapeutic Option
February 22, 2024 07:47 ET
|
ZyVersa Therapeutics
Activation of multiple inflammasome pathways and extracellular ASC specks contribute to development and progression of common neurological diseases.
ZyVersa Therapeutics Highlights Review Article Substantiating That Inflammasome Activation Is Pathogenic in Multiple Neurological Diseases
February 14, 2024 07:53 ET
|
ZyVersa Therapeutics
Inflammation resulting from activation of more than one type inflammasome and ASC specks contribute to development and progression of neurological disease
ZyVersa Therapeutics' CEO, Stephen C. Glover to Present at the 2024 BIO CEO & Investor Conference to Provide Corporate Update and Discuss Key Milestones
February 07, 2024 08:02 ET
|
ZyVersa Therapeutics
ZyVersa CEO will discuss development milestones for Cholesterol Efflux Mediator VAR 200 and Inflammasome ASC Inhibitor IC 100 at BIO CEO & Investor Conf.
ZyVersa Therapeutics Highlights Publication Indicating That Inflammasome NLRP3-Mediated Inflammation in Obese Children Leads to Insulin Resistance and Risk of Complications Such as Type 2 Diabetes
January 31, 2024 07:57 ET
|
ZyVersa Therapeutics
NLRP3-Mediated Inflammation in Obese Children Leads to Insulin Resistance and Risk of Complications (e.g., Type 2 Diabetes, Hypertension, Heart Disease).
ZyVersa Therapeutics Announces Peer-Reviewed Article Supporting the Therapeutic Potential of Targeting ASC Specks During Progression of Alzheimer’s Disease
January 24, 2024 07:57 ET
|
ZyVersa Therapeutics
Activation of the inflammasome/ASC speck pathway has a vital role in synaptic degeneration in Alzheimer’s Disease (AD).
ZyVersa Therapeutics Highlights Peer-Reviewed Article Linking Inflammasome Activation to Triple-Negative Breast Cancer Brain Metastasis
January 17, 2024 07:52 ET
|
ZyVersa Therapeutics
NLRP3 Inflammasome Activation Is Linked to Brain Metastasis in Patients with Triple-Negative Breast Cancer.
ZyVersa Therapeutics’ CEO, Stephen C. Glover, Featured on Benzinga All Access
January 10, 2024 08:06 ET
|
ZyVersa Therapeutics
View ZyVersa Therapeutics' Benzinga All Access Interview To Learn About Key Development Milestones in 2024.
ZyVersa Therapeutics Announces Equity Research Coverage Initiated by Noble Capital Markets
January 04, 2024 07:50 ET
|
ZyVersa Therapeutics
ZyVersa is developing two proprietary product platforms targeting renal and inflammatory diseases. Cholesterol Efflux MediatorTM VAR 200, designed to ameliorate renal lipid accumulation that...
ZyVersa Therapeutics CEO, Stephen C. Glover, Issues Letter to Shareholders Providing Outlook for 2024
January 03, 2024 08:07 ET
|
ZyVersa Therapeutics
WESTON, Fla., Jan. 03, 2024 (GLOBE NEWSWIRE) -- ZyVersa Therapeutics, Inc. (Nasdaq: ZVSA; “ZyVersa”), a clinical stage specialty biopharmaceutical company developing first-in-class drugs for...